A Danish Duo’s African Research Gains Momentum in RFK Jr.’s Vaccine Policy

In a modest Copenhagen office, epidemiologists Peter Aaby and Christine Stabell Benn have spent two decades documenting health outcomes in rural West Africa, where their findings on measles and tetanus vaccination have repeatedly challenged prevailing vaccine narratives. Their partnership with local health ministries and NGOs has generated data that are both praised for their depth and contested for their extrapolation to broader populations. Their work, largely published in peer‑reviewed journals and presented at regional conferences, argues that current vaccine efficacy estimates overstate protection, suggesting that natural immunity and targeted delivery can achieve comparable mortality reductions at lower cost. Critics have dismissed these claims as methodological bias, yet the couple’s large‑scale, longitudinal datasets collected across several thousand children offer a rare granularity that mainstream models lack. The researchers employ propensity‑score matching and adjust for socioeconomic confounders, yet critics argue that unmeasured variables such as nutritional status may bias results. The timing of their resurgence coincides with Robert F. Kennedy Jr.’s appointment as the United States’ top health official, a move that has reinvigorated skepticism toward established immunization programs. Kennedy’s public statements questioning vaccine safety and advocating for more transparency have opened a political window for alternative research to influence policy discussions, especially in states where vaccine hesitancy remains high. If Aaby and Stabell Benn’s evidence gains regulatory credibility, it could reshape funding priorities, prompting trials that test less intensive vaccination schedules or alternative delivery mechanisms. However, the scientific community warns that policy shifts driven by selective data may undermine herd immunity, emphasizing the need for rigorous, transparent evaluation before any substantive revision of national vaccine strategies.